Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

By: Benzinga via Benzinga

November 21, 2015 at 20:54 PM EST

Exelixis, Inc. (NASDAQ: EXEL) today announced the presentation of positive overall survival (OS) results from coBRIM, ...

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.